MA37569B1 - Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc - Google Patents
Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gccInfo
- Publication number
- MA37569B1 MA37569B1 MA37569A MA37569A MA37569B1 MA 37569 B1 MA37569 B1 MA 37569B1 MA 37569 A MA37569 A MA 37569A MA 37569 A MA37569 A MA 37569A MA 37569 B1 MA37569 B1 MA 37569B1
- Authority
- MA
- Morocco
- Prior art keywords
- gcc
- antibody molecules
- relates
- methods
- immunoconjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La présente invention concerne des anticorps et des fragments liant les antigènes d'anticorps liant la gcc. L'invention concerne également des méthodes de diagnostic permettant d'identifier des patients qui devraient recevoir une thérapie ciblée sur la gcc utilisant les anticorps anti-gcc de la présente invention. Les molécules d'anticorps anti-gcc peuvent être utilisées en tant que molécules d'anticorps nus et en tant que composants d'immunoconjugués. En conséquence, selon un autre aspect, l'invention concerne des immunoconjugués comprenant une molécule d'anticorps anti-gcc selon la présente invention et un agent thérapeutique ou un marqueur. L'invention concerne également des méthodes d'utilisation des molécules d'anticorps anti-gcc et des immunoconjugués décrits ici, par exemple en vue de la détection de la gcc et de cellules ou de tissus exprimant la gcc. Lesdites méthodes peuvent être utilisées, entre autres, en vue du diagnostic, du pronostic, de l'imagerie ou de la détermination des stades d'une maladie évolutive à médiation par la gcc. En conséquence, selon certains aspects, l'invention concerne des méthodes d'identification d'un sujet devant faire l'objet d'un traitement par une thérapie ciblée sur la gcc, par exemple une thérapie à base d'anticorps anti-gcc, faisant notamment appel à un immunoconjugué comprenant un anticorps anti-gcc conjugué à un agent thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639376P | 2012-04-27 | 2012-04-27 | |
PCT/US2013/038542 WO2013163633A1 (fr) | 2012-04-27 | 2013-04-27 | Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37569B1 true MA37569B1 (fr) | 2020-08-31 |
Family
ID=49477498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37569A MA37569B1 (fr) | 2012-04-27 | 2013-04-27 | Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc |
Country Status (41)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG179567A1 (en) | 2009-10-23 | 2012-05-30 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods |
EP3060580B1 (fr) * | 2013-10-21 | 2021-03-31 | Centre For Drug Research And Development | Anticorps anti-podocalyxine et leurs méthodes d'utilisation |
US10351897B2 (en) | 2014-02-14 | 2019-07-16 | Bioventures, Llc | Acetaminophen adducts and methods of use thereof |
JP6785239B2 (ja) | 2014-12-03 | 2020-11-18 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC | 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 |
AU2016333175B2 (en) | 2015-10-01 | 2023-08-24 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
CN110268108B (zh) | 2016-12-12 | 2022-09-06 | 埃克切拉生物科学公司 | 用于使用微毛细管阵列进行筛选的方法和系统 |
KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
JP7197584B2 (ja) * | 2017-12-06 | 2022-12-27 | ベンタナ メディカル システムズ, インコーポレイテッド | デジタル病理学分析結果の格納および読み出し方法 |
US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2021205325A1 (fr) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anticorps anti-gucy2c et leurs utilisations |
CA3176119A1 (fr) * | 2020-06-02 | 2021-12-09 | Teijin Pharma Limited | Anticorps humanise de recepteur anti-igf-1 |
IL303610A (en) * | 2020-12-17 | 2023-08-01 | Parasol Biotech Ltd | GUCY2C binding molecules and their uses |
WO2024067762A1 (fr) * | 2022-09-28 | 2024-04-04 | Nanjing Legend Biotech Co., Ltd. | Anticorps et récepteurs antigéniques chimériques ciblant gcc et leurs procédés d'utilisation |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US6060037A (en) | 1993-10-26 | 2000-05-09 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
WO1997042506A1 (fr) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Procedes et trousses de diagnostic et compositions permettant de diagnostiquer des tumeurs colorectales et leurs metastases |
CA2254082C (fr) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Vaccin contre le cancer recto-colique metastatique |
US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
ES2346637T3 (es) | 2000-03-27 | 2010-10-19 | Thomas Jefferson University | Composiciones y metodos para identificar y marcar celulas cancerosas originadas en el tubo digestivo. |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
DK1377314T3 (da) | 2001-01-26 | 2011-12-12 | Inhibitex Inc | Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner |
DK1379224T4 (da) | 2001-03-29 | 2013-12-02 | Synergy Pharmaceuticals Inc | Guanylat-cyklase-receptoragonister til behandling af vævsbetændelse og karcinogenese |
NZ529494A (en) | 2001-04-13 | 2005-08-26 | Biogen Idec Inc | Antibodies to VLA-1 |
DE60220719T2 (de) | 2001-12-28 | 2008-03-06 | Amgen Fremont Inc. | Antikörper gegen das muc18-antigen |
US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004071436A2 (fr) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | Utilisation de ligands gcc |
US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
EP1781339B1 (fr) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Ligands de la Guanylyle cyclase C |
EP1838733B1 (fr) | 2004-12-21 | 2011-08-24 | Medimmune Limited | Anticorps diriges contre l'angiopoietine 2 et leurs utilisations |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
CA2696011A1 (fr) * | 2007-08-10 | 2009-02-19 | Centocor Ortho Biotech Inc. | Fragments de clivage d'immunoglobulines utilises comme indicateurs de maladies, et compositions permettant de detecter et de fixer ces fragments |
MY153781A (en) | 2007-08-10 | 2015-03-13 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
PL2220492T3 (pl) * | 2007-11-30 | 2012-01-31 | Genentech Inc | Polimorfizmy VEGF oraz terapia antyangiogenna |
US20110195415A1 (en) | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
ES2559840T3 (es) | 2008-06-04 | 2016-02-16 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
EP3241839B1 (fr) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
EP2370098A4 (fr) * | 2008-12-03 | 2013-07-17 | Morphosys Ag | Anticorps contre les récepteurs de guanylyle cyclase |
US9364477B2 (en) * | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
WO2010096929A1 (fr) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Procédé de détection de métastase d'un cancer du tractus gastro-intestinal |
JPWO2010104035A1 (ja) * | 2009-03-12 | 2012-09-13 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
CA2801729A1 (fr) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions et procedes d'activation de la guanylyl cyclase c |
EP3444333A1 (fr) | 2009-10-22 | 2019-02-20 | Thomas Jefferson University | Compositions anticancéreuses a base de cellules et leurs procédés de fabrication et d'utilisation |
SG179567A1 (en) * | 2009-10-23 | 2012-05-30 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods |
WO2011150454A1 (fr) * | 2010-06-01 | 2011-12-08 | Monash University | Anticorps dirigés contre le récepteur tyrosine kinase c-met |
JP2013539460A (ja) * | 2010-08-13 | 2013-10-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベバシズマブ併用療法のためのバイオマーカーとしてのニューロピリン |
US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
CN105142664A (zh) * | 2013-02-28 | 2015-12-09 | 米伦纽姆医药公司 | 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症 |
-
2013
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en unknown
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/fr unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 CA CA2871614A patent/CA2871614C/fr active Active
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/fr active Application Filing
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko active IP Right Grant
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/fr active Active
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en active Active
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
-
2014
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399A1/en unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
- 2015-09-02 HK HK15108592.8A patent/HK1208049A1/xx unknown
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-18 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37569B1 (fr) | Molécules d'anticorps anti-gcc et leur utilisation en vue de tester la sensibilité à une thérapie ciblée sur la gcc | |
Lim et al. | Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia | |
MA44101B1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
MA42381A (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
MA46647A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA43458A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
MA46022B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
MA46504A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA49158B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
AR070168A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos | |
WO2008103645A8 (fr) | Antigènes spécifiques du cancer de la prostate et du mélanome | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
WO2015014903A3 (fr) | Instruments de diagnostic pour la maladie d'alzheimer | |
ECSP15028696A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos | |
Libner et al. | Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis | |
Kim et al. | In Situ Detection of HY-Specific T Cells in Acute Graft-versus-Host Disease–Affected Male Skin after Sex-Mismatched Stem Cell Transplantation | |
Arrieta et al. | Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas | |
MA34291B1 (fr) | Compositions et méthodes de diagnostic et de traitement d'une tumeur | |
Ermaya et al. | Correlation between Endoscopy Finding with Clinical Manifestations of Recurrent Abdominal Pain and Helicobacter pylori Infection | |
Ravenni et al. | VALIDATION OF NEUROTENSIN TETRA-BRANCHED PEPTIDES AS TUMOR TARGETING AGENTS IN PANCREAS, COLON AND BLADDER CARCINOMA |